| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [L. J. L.], and Departments of Human Oncology and Pharmacology, University of Wisconsin Clinical Cancer Center, Madison, Wisconsin 53792 [V. C. J.]
This paper describes the laboratory discovery and clinical testing of the first nonsteroidal antiestrogen, MER-25 (ethamoxytriphetol). The compound blocks estrogen action in all species tested and has only slight but transient estrogenic effects. No other antisteroidal actions are noted. MER-25 is antiestrogenic in primates and was investigated in the clinics in a wide range of gynecological conditions, including breast and endometrial cancer. Unfortunately toxic side effects (hallucinations, etc.) precluded further investigation. A derivative of triphenylethylene, clomiphene, has some partial agonist (estrogen-like) actions in laboratory animals and following clinical evaluation is now an established agent for the induction of ovulation in subfertile women. Although clomiphene is active in advanced breast cancer, it was not developed further. In the late 1960s a related compound, tamoxifen, was evaluated to treat a number of estrogen-responsive disorders but was successfully introduced in the 1970s for the treatment of advanced breast cancer. Although there was only modest initial interest in the palliative use of tamoxifen, an enormous increase in basic and applied studies with antiestrogens resulted in a definition of the target site-specific and tumoristatic actions of tamoxifen. Close cooperation between laboratory and clinical evaluation has guided the subsequent development of tamoxifen which is now available to treat all stages of breast cancer. Long-term adjuvant tamoxifen therapy, a concept developed in the laboratory, is currently the treatment strategy of choice. The considerable success of tamoxifen has focused attention on new antiestrogens with different pharmacological properties for other potential clinical applications.
1 Presented at the 80th Annual Meeting of the American Association for Cancer Research, May 24, 1989, San Francisco, CA.
This article has been cited by other articles:
|
|
 |
|
  V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Rise of Raloxifene and the Fall of Invasive Breast Cancer J Natl Cancer Inst, June 18, 2008; 100(12): 831 - 833. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kapoor and J. J. Sheng Transfection of Human Prostate Cancer CA-HPV-10 Cells with Cytosolic Sulfotransferase SULT1E1 Affects Estrogen Signaling and Gene Transcription Drug Metab. Dispos., February 1, 2008; 36(2): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2207 - 2209. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan SERMs: Meeting the Promise of Multifunctional Medicines J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Terry, W. C. Willett, J. W. Rich-Edwards, and K. B. Michels A Prospective Study of Infertility Due to Ovulatory Disorders, Ovulation Induction, and Incidence of Breast Cancer Arch Intern Med, December 11, 2006; 166(22): 2484 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice Clin. Cancer Res., September 1, 2006; 12(17): 5010 - 5013. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Chemoprevention in the 21st Century: Is a Balance Best or Should Women Have No Estrogen at All? J. Clin. Oncol., March 10, 2005; 23(8): 1598 - 1600. [Full Text] [PDF]
|
|
|
|
|
|
B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Osipo, H. Liu, K. Meeke, and V. C. Jordan The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Dardes, R. M. O'Regan, C. Gajdos, S. P. Robinson, D. Bentrem, A. De Los Reyes, and V. C. Jordan Effects of a New Clinically Relevant Antiestrogen (GW5638) Related to Tamoxifen on Breast and Endometrial Cancer Growth in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1995 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Selective Estrogen Receptor Modulation: A Personal Perspective Cancer Res., August 1, 2001; 61(15): 5683 - 5687. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Nazarenko, S. D. Dertinger, and T. A. Gasiewicz In Vivo Antagonism of AhR-Mediated Gene Induction by 3'-Methoxy-4'-nitroflavone in TCDD-Responsive lacZ Mice Toxicol. Sci., June 1, 2001; 61(2): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Estrogen, Selective Estrogen Receptor Modulation, and Coronary Heart Disease: Something or Nothing J Natl Cancer Inst, January 3, 2001; 93(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
S. Miller, D. Kennedy, J. Thomson, F. Han, R. Smith, N. Ing, J. Piedrahita, and D. Busbee A Rapid and Sensitive Reporter Gene that Uses Green Fluorescent Protein Expression to Detect Chemicals with Estrogenic Activity Toxicol. Sci., May 1, 2000; 55(1): 69 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Tamoxifen: Too Much of a Good Thing? J. Clin. Oncol., September 1, 1999; 17(9): 2629 - 2629. [Full Text] [PDF]
|
|
|
|
 |
|
 V C. Jordan and M Morrow Raloxifene as a multifunctional medicine? BMJ, August 7, 1999; 319(7206): 331 - 332. [Full Text]
|
|
|
|
 |
|
 V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Sauvez, D. S. Drouin, M. Attia, H. Bertheux, and R. Forster Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats Carcinogenesis, May 1, 1999; 20(5): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Mgbonyebi, J. Russo, and I. H. Russo Roscovitine Induces Cell Death and Morphological Changes Indicative of Apoptosis in MDA-MB-231 Breast Cancer Cells Cancer Res., April 1, 1999; 59(8): 1903 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Turner, G. L. Evans, J. P. Sluka, M. D. Adrian, H. U. Bryant, C. H. Turner, and M. Sato Differential Responses of Estrogen Target Tissues in Rats Including Bone to Clomiphene, Enclomiphene, and Zuclomiphene Endocrinology, September 1, 1998; 139(9): 3712 - 3720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Z. Ke, V. M. Paralkar, W. A. Grasser, D. T. Crawford, H. Qi, H. A. Simmons, C. M. Pirie, K. L. Chidsey-Frink, T. A. Owen, S. L. Smock, et al. Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models Endocrinology, April 1, 1998; 139(4): 2068 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tremblay, G. B. Tremblay, C. Labrie, F. Labrie, and V. Giguere EM-800, a Novel Antiestrogen, Acts as a Pure Antagonist of the Transcriptional Functions of Estrogen Receptors {alpha} and {beta} Endocrinology, January 1, 1998; 139(1): 111 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Jimenez, D. E. Magee, H. U. Bryant, and R. T. Turner Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats Endocrinology, May 1, 1997; 138(5): 1794 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Williams, H. C. Blair, M. A. McKenna, S. E. Jordan, and J. M. McDonald Regulation of Avian Osteoclastic H[IMAGE]-ATPase and Bone Resorption by Tamoxifen and Calmodulin Antagonists J. Biol. Chem., May 24, 1996; 271(21): 12488 - 12495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huynh, X. Yang, and M. Pollak Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells J. Biol. Chem., January 12, 1996; 271(2): 1016 - 1021. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
